Market Cap ₹84730 Cr.
Stock P/E 44.3
P/B 9
Current Price ₹2114.9
Book Value ₹ 233.8
Face Value 1
52W High ₹2488.7
Dividend Yield 0%
52W Low ₹ 1240.8
Mankind Pharma Ltd is a pharmaceutical company based in India that specializes in developing and manufacturing a wide range of affordable generic medicines, over-the-counter (OTC) products, and healthcare devices. Established in 1995, Mankind Pharma has a strong presence in the Indian pharmaceutical market and operates in more than 34 countries across the globe. The company has a portfolio of more than 1,000 products, covering therapeutic areas such as cardiology, neurology, gastroenterology, and anti-infectives. Mankind Pharma has a state-of-the-art R&D center, which focuses on developing innovative and cost-effective drugs and medical devices. The company is committed to providing high-quality healthcare products at affordable prices and has won several awards for its contribution to the pharmaceutical industry.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1726 | 2180 | 2426 | 2091 | 2053 | 2579 | 2708 | 2607 | 2441 |
| Other Income | 34 | 17 | 27 | 37 | 48 | 59 | 60 | 70 | 92 |
| Total Income | 1759 | 2197 | 2453 | 2128 | 2100 | 2637 | 2768 | 2677 | 2533 |
| Total Expenditure | 1441 | 1724 | 1835 | 1654 | 1636 | 1924 | 2025 | 2000 | 1850 |
| Operating Profit | 318 | 473 | 618 | 474 | 464 | 713 | 743 | 677 | 683 |
| Interest | 13 | 16 | 10 | 13 | 5 | 6 | 9 | 9 | 9 |
| Depreciation | 47 | 78 | 79 | 85 | 85 | 87 | 96 | 110 | 105 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 258 | 378 | 529 | 377 | 375 | 620 | 638 | 558 | 569 |
| Provision for Tax | 70 | 84 | 110 | 83 | 84 | 130 | 130 | 103 | 95 |
| Profit After Tax | 188 | 294 | 419 | 293 | 291 | 489 | 508 | 455 | 474 |
| Adjustments | 2 | -2 | 1 | -9 | -5 | -3 | -7 | -1 | -3 |
| Profit After Adjustments | 190 | 293 | 420 | 284 | 285 | 487 | 501 | 454 | 471 |
| Adjusted Earnings Per Share | 4.7 | 7.3 | 10.5 | 7.1 | 7.1 | 12.2 | 12.5 | 11.3 | 11.8 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 3323 | 3944 | 4382 | 4921 | 4980 | 5872 | 6214 | 7782 | 8749 | 10335 |
| Other Income | 76 | 71 | 89 | 72 | 53 | 104 | 171 | 196 | 129 | 281 |
| Total Income | 3399 | 4015 | 4471 | 4993 | 5033 | 5976 | 6385 | 7978 | 8878 | 10615 |
| Total Expenditure | 2738 | 3185 | 3531 | 3927 | 4055 | 4427 | 4565 | 5791 | 6848 | 7799 |
| Operating Profit | 662 | 830 | 940 | 1066 | 978 | 1548 | 1820 | 2187 | 2030 | 2816 |
| Interest | 2 | 3 | 4 | 25 | 44 | 23 | 21 | 60 | 46 | 33 |
| Depreciation | 39 | 43 | 31 | 46 | 69 | 99 | 119 | 167 | 326 | 398 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 621 | 784 | 906 | 995 | 875 | 1438 | 1692 | 1975 | 1671 | 2385 |
| Provision for Tax | 177 | 244 | 290 | 323 | 264 | 382 | 399 | 522 | 362 | 458 |
| Profit After Tax | 444 | 540 | 616 | 672 | 610 | 1056 | 1293 | 1453 | 1310 | 1926 |
| Adjustments | -5 | 2 | 13 | -15 | -32 | -26 | -28 | -19 | -28 | -14 |
| Profit After Adjustments | 439 | 542 | 629 | 656 | 579 | 1030 | 1265 | 1433 | 1282 | 1913 |
| Adjusted Earnings Per Share | 11 | 13.5 | 15.7 | 16.4 | 14.4 | 25.7 | 31.6 | 35.8 | 32 | 47.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 12% | 14% | 12% | 0% |
| Operating Profit CAGR | -7% | 9% | 14% | 0% |
| PAT CAGR | -10% | 7% | 14% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 56% | NA% | NA% | NA% |
| ROE Average | 19% | 26% | 26% | 25% |
| ROCE Average | 23% | 32% | 34% | 34% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 2055 | 2257 | 2927 | 2881 | 2823 | 3485 | 4722 | 6155 | 7435 |
| Minority's Interest | 16 | 29 | 98 | 134 | 159 | 186 | 141 | 161 | 188 |
| Borrowings | 0 | 2 | 3 | 3 | 25 | 58 | 58 | 49 | 23 |
| Other Non-Current Liabilities | 28 | 32 | 51 | 46 | 53 | 45 | 50 | 119 | 176 |
| Total Current Liabilities | 433 | 528 | 663 | 1296 | 1024 | 1251 | 1353 | 2623 | 1863 |
| Total Liabilities | 2532 | 2848 | 3741 | 4360 | 4084 | 5025 | 6324 | 9108 | 9686 |
| Fixed Assets | 277 | 447 | 793 | 1014 | 1399 | 1594 | 1659 | 3583 | 4245 |
| Other Non-Current Assets | 582 | 695 | 879 | 773 | 686 | 609 | 758 | 1119 | 1113 |
| Total Current Assets | 1673 | 1707 | 2069 | 2574 | 1943 | 2820 | 3880 | 4404 | 4325 |
| Total Assets | 2532 | 2848 | 3741 | 4360 | 4084 | 5025 | 6324 | 9108 | 9686 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 98 | 53 | 82 | 89 | 136 | 116 | 220 | 127 | 283 |
| Cash Flow from Operating Activities | 280 | 537 | 628 | 639 | 600 | 1072 | 1137 | 920 | 1813 |
| Cash Flow from Investing Activities | -348 | -152 | -625 | -505 | -444 | -439 | -1222 | -1369 | -1054 |
| Cash Flow from Financing Activities | 9 | -361 | 2 | -89 | -175 | -527 | -8 | 605 | -740 |
| Net Cash Inflow / Outflow | -59 | 25 | 5 | 46 | -19 | 106 | -93 | 155 | 19 |
| Closing Cash & Cash Equivalent | 39 | 78 | 87 | 135 | 116 | 226 | 127 | 283 | 305 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 10.97 | 13.53 | 15.71 | 16.39 | 14.44 | 25.72 | 31.59 | 35.78 | 32 |
| CEPS(Rs) | 12.05 | 14.57 | 16.14 | 17.91 | 16.96 | 28.84 | 35.25 | 40.43 | 40.83 |
| DPS(Rs) | 0 | 15 | 0 | 4.35 | 4.45 | 3.1 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 51.29 | 56.34 | 73.07 | 71.92 | 70.47 | 87 | 117.88 | 153.65 | 185.61 |
| Core EBITDA Margin(%) | 17.56 | 19.12 | 19.26 | 20.15 | 18.57 | 23.68 | 25.5 | 24.66 | 20.89 |
| EBIT Margin(%) | 18.68 | 19.81 | 20.58 | 20.68 | 18.45 | 23.95 | 26.49 | 25.21 | 18.86 |
| Pre Tax Margin(%) | 18.62 | 19.74 | 20.5 | 20.17 | 17.56 | 23.57 | 26.16 | 24.47 | 18.35 |
| PAT Margin (%) | 13.32 | 13.6 | 13.94 | 13.62 | 12.26 | 17.31 | 20 | 18 | 14.38 |
| Cash Profit Margin (%) | 14.47 | 14.7 | 14.64 | 14.55 | 13.64 | 18.94 | 21.84 | 20.07 | 17.96 |
| ROA(%) | 17.54 | 20.08 | 18.69 | 16.58 | 14.46 | 23.19 | 22.79 | 18.83 | 13.94 |
| ROE(%) | 21.61 | 25.06 | 23.76 | 23.13 | 21.41 | 33.48 | 31.51 | 26.72 | 19.27 |
| ROCE(%) | 30.32 | 36.47 | 34.98 | 32.75 | 28.8 | 43.57 | 39.97 | 33.96 | 23.49 |
| Receivable days | 21.57 | 17.91 | 14.83 | 17.14 | 18.94 | 22.48 | 24.32 | 16.25 | 19.33 |
| Inventory Days | 65.27 | 55.86 | 58.15 | 58.39 | 59.01 | 51.46 | 58.78 | 66.57 | 65.31 |
| Payable days | 99.58 | 94.07 | 104.83 | 124.64 | 128.4 | 127.01 | 144.73 | 131.38 | 130.57 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | -0.01 | -0.02 | -0.03 | 0.06 | 0.03 | -0.04 | -0.07 | 0.06 | -0.03 |
| EV/Core EBITDA(x) | -0.03 | -0.08 | -0.12 | 0.29 | 0.17 | -0.16 | -0.23 | 0.23 | -0.12 |
| Net Sales Growth(%) | 0 | 18.67 | 11.12 | 12.29 | 1.2 | 17.91 | 5.83 | 25.22 | 12.44 |
| EBIT Growth(%) | 0 | 26.28 | 15.58 | 12.17 | -9.91 | 59 | 17.23 | 18.78 | -15.6 |
| PAT Growth(%) | 0 | 21.66 | 14.01 | 9.08 | -9.13 | 73 | 22.43 | 12.37 | -9.86 |
| EPS Growth(%) | 0 | 23.38 | 16.07 | 4.34 | -11.88 | 78.11 | 22.81 | 13.28 | -10.58 |
| Debt/Equity(x) | 0 | 0 | 0 | 0.14 | 0.1 | 0.04 | 0.05 | 0.14 | 0.02 |
| Current Ratio(x) | 3.86 | 3.24 | 3.12 | 1.99 | 1.9 | 2.25 | 2.87 | 1.68 | 2.32 |
| Quick Ratio(x) | 2.48 | 2.1 | 1.97 | 1.39 | 1.1 | 1.54 | 2.05 | 1.01 | 1.52 |
| Interest Cover(x) | 289.38 | 289.77 | 249.67 | 40.44 | 20.77 | 62.87 | 80.96 | 34.02 | 37.52 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Promoter | 76.5 | 76.5 | 76.5 | 76.5 | 74.88 |
| FII | 2.61 | 4.18 | 4.18 | 6.74 | 9.87 |
| DII | 2.64 | 4.64 | 4.56 | 9.79 | 11.14 |
| Public | 18.25 | 14.68 | 14.76 | 6.97 | 4.11 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Promoter | 30.65 | 30.65 | 30.65 | 30.65 | 30 |
| FII | 1.05 | 1.67 | 1.68 | 2.7 | 3.96 |
| DII | 1.06 | 1.86 | 1.83 | 3.92 | 4.46 |
| Public | 7.31 | 5.88 | 5.91 | 2.79 | 1.65 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 40.06 | 40.06 | 40.06 | 40.06 | 40.06 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
